Sunil Reddy

7.2k total citations
72 papers, 2.7k citations indexed

About

Sunil Reddy is a scholar working on Oncology, Molecular Biology and Dermatology. According to data from OpenAlex, Sunil Reddy has authored 72 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 23 papers in Molecular Biology and 23 papers in Dermatology. Recurrent topics in Sunil Reddy's work include CAR-T cell therapy research (22 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Cutaneous lymphoproliferative disorders research (19 papers). Sunil Reddy is often cited by papers focused on CAR-T cell therapy research (22 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Cutaneous lymphoproliferative disorders research (19 papers). Sunil Reddy collaborates with scholars based in United States, United Kingdom and Germany. Sunil Reddy's co-authors include Youn H. Kim, Richard T. Hoppe, Susan M. Swetter, Susan M. Hiniker, Madeleine Duvic, Susan J. Knox, Sabine Köhler, Adam Lerner, Ellen J. Kim and Jürgen C. Becker and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

In The Last Decade

Sunil Reddy

66 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sunil Reddy United States 24 1.1k 860 822 746 704 72 2.7k
Ian Walters United States 22 542 0.5× 615 0.7× 478 0.6× 1.1k 1.4× 409 0.6× 58 2.6k
Joost J. Oudejans Netherlands 34 1.3k 1.2× 717 0.8× 308 0.4× 815 1.1× 1.3k 1.8× 68 3.0k
Gerald Höfler Austria 24 945 0.9× 519 0.6× 469 0.6× 327 0.4× 756 1.1× 61 2.6k
Magdalena Martinka Canada 26 728 0.7× 1.2k 1.4× 330 0.4× 444 0.6× 348 0.5× 62 2.3k
M Stetler-Stevenson United States 22 869 0.8× 680 0.8× 161 0.2× 735 1.0× 677 1.0× 44 2.3k
Larisa J. Geskin United States 27 776 0.7× 370 0.4× 1.2k 1.5× 781 1.0× 830 1.2× 162 2.3k
Ruby Phelps United States 20 985 0.9× 668 0.8× 441 0.5× 252 0.3× 419 0.6× 26 2.0k
Francine M. Foss United States 36 1.8k 1.7× 1.7k 1.9× 2.2k 2.6× 2.1k 2.8× 2.8k 4.0× 170 5.2k
Shigeru Kusumoto Japan 28 748 0.7× 622 0.7× 222 0.3× 1.0k 1.3× 449 0.6× 144 2.7k
Bjarni A. Agnarsson Iceland 27 714 0.7× 925 1.1× 331 0.4× 344 0.5× 854 1.2× 80 2.7k

Countries citing papers authored by Sunil Reddy

Since Specialization
Citations

This map shows the geographic impact of Sunil Reddy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sunil Reddy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sunil Reddy more than expected).

Fields of papers citing papers by Sunil Reddy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sunil Reddy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sunil Reddy. The network helps show where Sunil Reddy may publish in the future.

Co-authorship network of co-authors of Sunil Reddy

This figure shows the co-authorship network connecting the top 25 collaborators of Sunil Reddy. A scholar is included among the top collaborators of Sunil Reddy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sunil Reddy. Sunil Reddy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nguyen, David, BaDoi N. Phan, & Sunil Reddy. (2024). Abscopal Effect in Metastatic Melanoma: Generating Clinical Insights From Radiation-Induced Immune Response. Cureus. 16(11). e72853–e72853.
2.
Kirane, Amanda, Michael Lowe, Saurabh Sharma, et al.. (2023). 622 Immune phenotype and iFRET functional analysis are biomarkers of response to neoadjuvant intralesional therapy for high risk stage II melanoma. SHILAP Revista de lepidopterología. A709–A709.
3.
Zhu, Han, Francisco X. Galdos, Daniel Lee, et al.. (2022). Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis. Circulation. 146(4). 316–335. 103 indexed citations
4.
Hui, Caressa, Yufan Wu, Kevin Liu, et al.. (2022). Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma. Cureus. 14(11). e31838–e31838. 1 indexed citations
5.
Reddy, Sunil, et al.. (2022). Traffic Management For Cities. International Journal of Engineering Technology and Management Sciences. 337–341.
6.
Nakamoto, Ryusuke, Lisa C. Zaba, Tie Liang, et al.. (2021). Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy. Journal of Nuclear Medicine. 62(10). 1380–1383. 14 indexed citations
7.
Reddy, Sunil. (2021). The complexity of carcinosarcoma. PubMed. 35(3512). 814–814.
8.
Reddy, Sunil, et al.. (2020). “Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma”. American Journal of Ophthalmology Case Reports. 20. 100891–100891. 18 indexed citations
9.
Amin, Asim, Mohammed Milhem, Georgina V. Long, et al.. (2019). Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.. Journal of Clinical Oncology. 37(15_suppl). 9555–9555. 6 indexed citations
10.
Chang, Anne Lynn S., Duy Tran, Shufeng Li, et al.. (2018). Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. Journal of the American Academy of Dermatology. 80(2). 564–566. 78 indexed citations
11.
Reddy, Sunil. (2016). Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting. Critical Reviews in Oncology/Hematology. 106. 99–107. 28 indexed citations
12.
Kim, Ellen J., Youn H. Kim, Alain H. Rook, et al.. (2015). Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leukemia & lymphoma. 56(10). 2847–2854. 17 indexed citations
13.
Li, Yingmei, Wenying Pan, Ian D. Connolly, et al.. (2015). BMET-15TUMOR CELL FREE DNA IN CEREBRAL SPINAL FLUID REFLECTS TREATMENT RESPONSE IN LEPTOMENINGEAL METASTASIS. Neuro-Oncology. 17(suppl 5). v48.1–v48. 1 indexed citations
15.
Danial, Christina, Bharathi Lingala, Raymond R. Balise, et al.. (2013). Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. British Journal of Dermatology. 169(3). 673–676. 29 indexed citations
16.
Whittaker, Sean, Marie‐France Demierre, Ellen J. Kim, et al.. (2010). Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology. 28(29). 4485–4491. 480 indexed citations
17.
Duvic, Madeleine, Sunil Reddy, Lauren Pinter‐Brown, et al.. (2009). A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders. Clinical Cancer Research. 15(19). 6217–6224. 61 indexed citations
18.
Jones, Christopher R., Sabine Köhler, Sunil Reddy, et al.. (2009). Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma. Archives of Dermatology. 145(6). 667–74. 64 indexed citations
19.
Reddy, Sunil & Ronald Levy. (2004). Molecular rescue of tumour‐specific T cell receptor idiotype from T cell lymphomas. British Journal of Haematology. 124(5). 626–628. 1 indexed citations
20.
McCabe, Michael J., Kameshwar P. Singh, Sunil Reddy, et al.. (2000). Sensitivity of Myelomonocytic Leukemia Cells to Arsenite-Induced Cell Cycle Disruption, Apoptosis, and Enhanced Differentiation Is Dependent on the Inter-Relationship between Arsenic Concentration, Duration of Treatment, and Cell Cycle Phase. Journal of Pharmacology and Experimental Therapeutics. 295(2). 724–733. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026